Company Presentation April 2017 1 Agenda 01 Sart rtorius in in - PowerPoint PPT Presentation

Company Presentation April 2017 1

Agenda 01 Sart rtorius in in Brie rief 02 Biopr ioprocess S Solu olutio ions 03 Lab b Prod Products & Serv rvices 04 Sart rtorius 2020 2020 05 Appe ppendix ix

Sartorius in 2016 Internationally leading Biopr oproce ocess a and Labor borator ory Tech chnol ologie ogies P Provide ider ~ €1.3 .3bn bn ~€152 152 mn mn ~34% 4% ~44% 4% ~22% 2% Investments Sales revenue Americas EMEA Asia| Pacific 25. 25.0 % ~€325 325 mn mn EBITDA 1 margin Earnings 1 Listed since 1990; Part of German TecDax Sales revenue by region 3 Figures as of Dec. 31, 2016; 1 Underlying EBITDA (excluding extraordinary items)

Global Player with around 50 Sales and Production Sites Asia ia|Pacif ific ic Americas as India | Thailand | Singapore | Canada | USA: Mas- Vietnam | China | Malaysia | sachusetts | Michigan | South Korea | Japan | Australia New York, New Mexico, EMEA EM EA North Carolina, Pennsyl- vania, Colorado | Puerto Netherlands | Belgium | Ireland | UK | France | Spain | Rico | Mexico | Peru | Sweden | Finland | Denmark | Germany | Poland | Brazil | Argentina Austria | Hungary | Switzerland | Italy | Russia | Tunisia Sales Production and Production/Sales 4

More than 6,900 Employees Worldwide ~1,000 00 ~4,850 50 ~1,050 50 Asia|Pacific Americas EMEA 2,000 00 3,000 00 4,000 00 5,000 00 ~7,000 00 1996 1997 1998 1999 2001 2002 2003 2004 2005 2006 2008 2009 2010 2011 2013 2014 2016 Dis iscov over Sartor oriu ius 1995 2000 2007 2012 2015 2017 5 Figures as of Dec. 31, 2016

Our Corporate Values 6

Roots of Both Divisions Reach Far Back 1870 1870 1927 1927 University mechanician | Company founder Florenz Wilhelm Sartorius founds joint venture with Nobel laureate and creator of membrane filtration Sartorius invents short-beam analytical balance Richard Zsigmondy Weighi ghing ng Techno hnolog ogy Filtratio ation Core of Lab Division Mainstay of Bioprocess Division 7

Business Development Spanning More Than 140 Years 1870 870 Florenz Sartorius founds Mid id-90s 90s Positioning as precision machine workshop biopharma supplier 2007 007 Biotechnology Division merges with Stedim to Sartorius Stedim Biotech 1927 927 Membrane filter company is founded 2011 011 New Division Lab Products & Services; Acquisition Biohit LH Rebuilding after Second World War sinc nce 2012 012 Six Acquisitions 1990 990 Initial public in Bioprocess Solutions 2000 000 Acquisition 2017 017 Acquisitions of offering of B. Braun‘s fer- 2016 016 Acquisitions of Essen BioScience and mentation business IntelliCyt and ViroCyt Umetrics 1870 870 1930 930 1980 980 1995 995 Today ay Core company International Subsidiaries in Expansion into Asia Around 50 sites in Goettingen distribution Europe | North America worldwide 8

Two Divisions ~25% 25% ~75% 75% of sales of sales Biopro rocess ss Solu lutio ions Lab P Product cts & Service ces Innovative single-use prodcts and Premium lab instruments, consumables equipment for the manufacture of biologics and services for R&D, QA and QC 9 Share of Group sales based on figures as of Dec. 31, 2016

Agenda 01 Sartoriu orius i in Brie rief 02 Biopr ioprocess S Solu olutio ions 03 Lab b Prod Products & Serv rvices 04 Sart rtorius 2020 2020 05 Appe ppendix ix

What Are Biopharmaceuticals? ~20. 0.000 A 000 Atoms Living, genetically modified cells Production Injection | Infusion Advan vantag tages Chal allenges  First-time or improved treatment of serious illnesses,  R&D and production labor-intensive such as cancer, multiple sclerosis, rheumatism  High therapy costs: biologics ~ $50 vs.  Targets only diseased cells; fewer side effects chemical medications ~ $2 per day  New vaccines 11

Trend towards Manufacturing Single-use Technologies Past st Pres esen ent High initial cost + CAPEX reduction over entire lifecycle Considerable cleaning effort + Lower water and energy consumption Risk of cross-contamination + Higher flexibility 12

BPS Generates Around 75% of its Business with Single-use Products Equipment nt ~25% Single le-us use ~ €975 975mn. ~75% 13 Figures as of Dec. 31, 2016

Total Solution Provider across the Biopharma Process Chain Proce cess D ss Development nt Produ duction ion Cell Culture Media Fermentation Cell Harvesting Buffer | Preparation Purification Serv rvic ices 14

Leading Market Positions Worldwide TOP 3 Fluid Management #1 #1 Fermentation #1 #1 Filtration TO  >85 % of sales revenue generated from TOP 1-3 positions 15

Agenda 01 Sartoriu orius i in Brie rief 02 Biopr ioprocess S Solu olutio ions 03 Lab b Prod Products & Serv rvices 04 Sart rtorius 2020 2020 05 Appe ppendix ix

Research Labs Need Intelligent Lab Instruments  Assistance systems reduce user errors  Laboratory data are processed automatically  Ergonomic design minimizes physical strain 17

Quality Assurance Labs Accompany every Step of Food and Pharma Production  Sample collection  Quality assurance  Clearance  Documentation 18

These Products and Services are Must-Haves in Any Laboratory Lab Instr Lab I truments Consumabl bles Services Se  Balances  Syringe Filters  Installation  Pipettes  Microbiological  Servicing | Repair Test Kits  Lab Water Systems  Qualification (IQ/OQ)  Pipette Tips  Moisture Analyzers  Calibration  Training 19

Lab Portfolio Recently Expanded into Bioanalytics Unique system for real-time live-cell imaging and analysis Acquisition in April 2017 Award-winning technology for cell screening Acquisition in June 2016 Innovative platform for rapid virus quantification Acquisition in July 2016  Innovative and unique bioanalytical platforms, combined from instruments, reagents and software  Focus on customers from pharma/biotech and academia  Excellent fit between the two acquired companies and with existing LPS portfolio 20

Expansion of Direct Sales including eBusiness ls nnels Pharma | Biotech Distributors Sales Chann optimize Direct sales Academia expand eBusiness Sal Cl. Diagnostics| Food & build up Chemicals Beverage

Leading Market Positions Worldwide Lab Balances #2 #2 Pipettes #4 #4 Lab Filtration #3 #3 Microb. Analysis #2 #2 (membrane based)  Average global market share >10%  Significant growth potential, especially in USA and Asia 22

Agenda 01 Sartoriu orius in in Brie rief 02 Biopr ioprocess S Solu olutio ions 03 Lab b Prod Products & Serv rvices 04 Sart rtorius 2020 2020 05 Appe ppendix ix

Profitable Growth in Past 10 Years 1,300.3 40 1,114.8 35 30 887.3 891.2 845.7 25 733.1 25.0 659.3 23.6 622.7 611.6 602.1 20 21.0 521.1 19.5 19.0 18.6 16.7 15 15.3 14.1 13.7 13.1 10 5 0 2 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Underlying EBITDA 1 margin in % Sales revenue € in mn 1 Underlying EBITDA (adjusted for extraordinary items); 2 Including Intec (Intec sales revenue = shaded area) 24

Ambitious Growth Targets Up to 2020 Strate tegic I Initiati atives 2020 T 2020 Targe rgets Regi gional al ~€2bn bn. 1  North America: Gain market share  Asia | esp. China: Leverage strong market growth Sales Revenue Portfolio ~3/4 ~1/4  Expansion through alliances and acquisitions Organic Acquisitions  Own product development ~26 26 - 27% 27% 1 Infrastructure In EBITDA 2 margin  Expansion of production capacity  New global ERP system 1 Based on 2015 exchange rates; 2 Excluding extraordinary items 25

Regional Gain Market Share in North America; Leverage Strong Market Growth in Asia ~ +18% 8% ~ +14% 4% CAGR 1 Americas CAGR 1 Asia | Pacific Sales share 2 Americas Mississauga Bohemia Beijing Seoul 34% Ann Arbor Tokyo New Oxford Suzhou Shanghai Albuquerque Hanoi ~€1.3 bn. Hong Kong Mexico City Bangkok Yauco Bangalore 22% Asia |Pacific Kuala Lumpur Singapore Production | Sales Sales Production | Sales Sales North America: largest market Asia: strongest-growing for biopharma and lab products pharma and lab market 1 2011-2016, in constant currencies 2 Figures as of Dec. 31, 2016 26

Portfolio Complementary Alliances & Acquisitions Add to Growth Cellc llca ABER ER BD BD BioOut utsour urce BlueS eSen ens Lonza C a Cell C ll Cult lture M Media ia Metro troglas Intell lliC iCyt Südpa pack Medic ica Wave B e Biotec ech ViroCy Cyt Bio iohit it Liqui uid Hand ndling ng Toha ha Pla last st NIR O Onlin line kSep ep c-LEc Ecta ta TAP P Biosy syst stems LevTe Tech Bosch h Packagi ging Omnimark ark ProMe Metic ic em-tec em Sted tedim Biosy syst stems Corning ng TC TC Te Tech Aseptic As ic Technolo logie ies Umetri trics AllPure re SAFC Bioscienc nces B. Braun aun Biote tech h Inter ernati nationa nal Trace A Analy lytic ics Ess Essen BioScience Raumedi edic Bayer Technology S Services 2000 000 2017 017 Acqui uisitions ns | Allianc nces 27 27